Improvement of myocardial lipid accumulation and prevention of PGC-1α induction by fenofibrate

Molecular Medicine Reports

Volumn 5, Issue 6, 2012, Pages 1396-1400

  Li, Wen Yan ^a   Yao, Chun Xia ^a   Zhang, Shu Feng ^a   Wang, Shu Ling ^a   Wang, Tian Qi ^a   Xiong, Cheng Juan ^a   Li, Yue Bai ^a   Zang, Ming Xi ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Fenofibrate; Gene expression; Myocardial lipid; Peroxisome proliferator activated receptor coactivator 1

Indexed keywords

CYTOCHROME B; FENOFIBRATE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; THIOCTIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID OXIDATION; GENE EXPRESSION; HEART MITOCHONDRION; LIPID STORAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ACYL-COA DEHYDROGENASE; ANIMALS; CYTOCHROMES B; DOWN-REGULATION; FATTY ACIDS; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MICE; MITOCHONDRIA; MYOCARDIUM; NF-E2-RELATED FACTOR 1; OXIDATION-REDUCTION; SULFURTRANSFERASES; TRANS-ACTIVATORS; TRIGLYCERIDES;

MUS;

EID: 84860765089     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.841     Document Type: Article

References (37)

1. Gustafsson AB and Gottlieb RA: Heart mitochondria: gates of life and death. Cardiovasc Res 77: 334-343, 2008. (Pubitemid 351197632)
2. Maack C and O'Rourke B: Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol 102: 369-392, 2007. (Pubitemid 47278811)
3. Scarpulla RC: Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann NY Acad Sci 1147: 321-334, 2008.
4. Gabriel K, Egan B and Lithgow T: Tom40, the import channel of the mitochondrial outer membrane, plays an active role in sorting imported proteins. EMBO J 22: 2380-2386, 2003. (Pubitemid 36604977)
5. Padmalayam I, Hasham S, Saxena U and Pillarisetti S: Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes 58: 600-608, 2009.
6. Yusuf K, Jirapradittha J, Amin HJ, Yu W and Hasan SU: Neonatal ventricular tachyarrhythmias in medium chain acyl-CoA dehydrogenase deficiency. Neonatology 98: 260-264, 2010.
7. Miura S, Kai Y, Ono M and Ezaki O: Overexpression of peroxisome proliferator-activated receptor gamma coactivator-1 alpha down-regulates GLUT4 mRNA in skeletal muscles. J Biol Chem 278: 31385-31390, 2003. (Pubitemid 36994659)
8. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP and Lopaschuk GD: A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277: 4098-4103, 2002. (Pubitemid 34968667)
9. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP and Lopaschuk GD: Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 290: H87-H95, 2006.
10. Finck B, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD and Kelly DP: The cardiac phenotype induced by PPAR overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130, 2002. (Pubitemid 34052548)
11. Yamaguchi T, Matsushita S, Motojima K, Hirose F and Osumi T: MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor alpha. J Biol Chem 281: 14232-14240, 2006. (Pubitemid 43848351)
12. Asai T, Okumura K, Takahashi R, Matsui H, Numaguchi Y, Murakami H, Murakami R and Murohara T: Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency. Cardiovasc Res 70: 566-577, 2006.
13. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ and Leid M: Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J Biol Chem 274: 15901-15907, 1999.
14. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB and Arnett DK: Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets 10: 138-148, 2010.
15. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T and Yokota M: Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 41: 318-329, 2006. (Pubitemid 44080222)
16. Zambon A and Cusi K: The role of fenofibrate in clinical practice. Diab Vasc Dis Res 4 (Suppl 3): S15-20, 2007. (Pubitemid 350013473)
17. Srivastava RA: Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists. Eur J Pharmacol 607: 258-263, 2009.
18. Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen T, Severson DL, Clarke K, Berge RK and Aasum E: Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res 83: 519-526, 2009.
19. Glass CK: Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116: 556-560, 2006.
20. Finck BN: The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 73: 269-277, 2007.
21. Barish GD, Narkar VA and Evans RM: PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597, 2006. (Pubitemid 43326863)
22. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC and Kelly DP: Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor {gamma} coactivator-1 (PGC-1) signaling. Circ Heart Fail 4: 474-482, 2011.
23. Arany Z, He H, Lin J, et al: Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1: 259-271, 2005. (Pubitemid 43960608)
24. Huss JM and Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ Res 95: 568-578, 2004. (Pubitemid 39274371)
25. Najib J: Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 24: 2022-2050, 2002.
26. Balakumar P, Rohilla A and Mahadevan N: Pleiotropic actions of fenofibrate on the heart. Pharmacol Res 63: 8-12, 2011.
27. Erol A: PPARalpha activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients. Med Hypotheses 66: 1044-1045, 2006.
28. Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, Hao MX, Hou XY, Gong ML, Zhao YX, Bu PL and Zhang Y: Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension. J Cell Mol Med 13: 4444-4452, 2009.
29. Rose M, Balakumar P and Singh M: Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 80: 177-184, 2007. (Pubitemid 47230712)
30. Yuan J, Wu J and Han ZG: Fenofibrate improves energy metabolism and attenuates isoproterenol induced acute myocardial ischemic injury in rats via PPAR alpha activation. Zhonghua Xin Xue Guan Bing Za Zhi 36: 847-850, 2008 (In Chinese).
31. MacLellan WR and Schneider MD: Genetic dissection of cardiac growth control pathways. Annu Rev Physiol 62: 289-319, 2000. (Pubitemid 30618265)
32. Palomer X, Alvarez-Guardia D, Rodríguez-Calvo R, Coll T, Laguna JC, Davidson MM, Chan TO, Feldman AM and Vázquez-Carrera M: TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc Res 81: 703-712, 2009.
33. King KL, Young ME, Kerner J, Huang H, O'Shea KM, Alexson SE, Hoppel CL and Stanley WC: Diabetes or peroxisome proliferator- activated receptor alpha agonist increases mitochondrial thioesterase I activity in heart. J Lipid Res 48: 1511-1517, 2007. (Pubitemid 47312013)
34. Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK and Larsen TS: Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol 44: 201-209, 2008.
35. Chambers KT, Leone TC, Sambandam N, Kovacs A, Wagg CS, Lopaschuk GD, Finck BN and Kelly DP: Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem 286: 11155-11162, 2011.
36. Aasum E, Cooper M, Severson DL and Larsen TS: Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 83: 183-190, 2005. (Pubitemid 40695392)
37. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M and Larsen TS: Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 283: H949-H957, 2002.